...
首页> 外文期刊>BMC Complementary and Alternative Medicine >Insights into the mechanism of Arnebia euchroma on leukemia via network pharmacology approach
【24h】

Insights into the mechanism of Arnebia euchroma on leukemia via network pharmacology approach

机译:通过网络药理学方法探讨Arnebia Euchroma对白血病的机制

获取原文

摘要

Arnebia euchroma (A. euchroma) is a traditional Chinese medicine (TCM) used for the treatment of blood diseases including leukemia. In recent years, many studies have been conducted on the anti-tumor effect of shikonin and its derivatives, the major active components of A. euchroma. However, the underlying mechanism of action (MoA) for all the components of A. euchroma on leukemia has not been explored systematically. In this study, we analyzed the MoA of A. euchroma on leukemia via network pharmacology approach. Firstly, the chemical components and their concentrations in A. euchroma as well as leukemia-related targets were collected. Next, we predicted compound-target interactions (CTIs) with our balanced substructure-drug-target network-based inference (bSDTNBI) method. The known and predicted targets of A. euchroma and leukemia-related targets were merged together to construct A. euchroma-leukemia protein-protein interactions (PPIs) network. Then, weighted compound-target bipartite network was constructed according to combination of eight central attributes with concentration information through Cytoscape. Additionally, molecular docking simulation was performed to calculate whether the components and predicted targets have interactions or not. A total of 65 components of A. euchroma were obtained and 27 of them with concentration information, which were involved in 157 targets and 779 compound-target interactions (CTIs). Following the calculation of eight central attributes of targets in A. euchroma-leukemia PPI network, 37 targets with all central attributes greater than the median values were selected to construct the weighted compound-target bipartite network and do the KEGG pathway analysis. We found that A. euchroma candidate targets were significantly associated with several apoptosis and inflammation-related biological pathways, such as MAPK signaling, PI3K-Akt signaling, IL-17 signaling, and T cell receptor signaling pathways. Moreover, molecular docking simulation demonstrated that there were eight pairs of predicted CTIs had the strong binding free energy. This study deciphered that the efficacy of A. euchroma in the treatment of leukemia might be attributed to 10 targets and 14 components, which were associated with inhibiting leukemia cell survival and inducing apoptosis, relieving inflammatory environment and inhibiting angiogenesis.
机译:Arnebia Euchroma(A.Euchroma)是一种中药(TCM),用于治疗包括白血病在内的血液疾病。近年来,已经对世琴素及其衍生物的抗肿瘤作用,A. euchroma的主要活性组成部分进行了许多研究。然而,对白血病A.欧洲群体的所有组分的潜在机制(MOA)尚未系统地探讨了白血病。在这项研究中,我们通过网络药理学方法分析了A. euchroma对白血病的MoA。首先,收集化学成分及其浓度。收集了A. euchroma以及白血病相关靶标。接下来,我们通过我们平衡的子结构 - 药物 - 目标网络的推论(BSDTNBI)方法预测复合目标交互(CTI)。 A. euchroma和白血病相关靶标的已知和预测的靶标在一起,以构建A. euchroma-白血病蛋白质 - 蛋白质相互作用(PPI)网络。然后,根据通过Cytoscape的浓度信息的八个中心属性的组合构建加权复合靶二分网络。另外,进行分子对接模拟以计算组件和预测的目标是否具有相互作用。获得了65个组分A. euchroma,并含有27个浓度信息,其中参与157个靶标和779种复合靶相互作用(CTI)。在计算A.Euchroma-Leukemia PPI网络中八个靶标的靶标的中央属性之后,选择了37个靶标,所有中央属性大于中值值以构建加权复合靶二分网,并进行KEGG途径分析。我们发现A.欧盟候选靶标显着与多个细胞凋亡和炎症相关的生物途径相关,例如MAPK信号传导,PI3​​K-AKT信号传导,IL-17信号传导和T细胞受体信号传导途径。此外,分子对接模拟表明存在八对预测的CTI具有强烈的无限度能量。该研究破译了A.欧盟罗马治疗白血病的疗效可能归因于10个靶标和14种成分,其与抑制白血病细胞存活和诱导凋亡,缓解炎症环境和抑制血管生成相关。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号